-
Mashup Score: 0Impact of SCD on Quality of Life - 3 year(s) ago
Clinicians dive into the impact of sickle cell on quality of life and symptom management
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Secukinumab for Pediatric Plaque Psoriasis - 3 year(s) ago
Secukinumab is the only fully human biologic that directly inhibits IL-17A.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
This Just In! The #FDA has approved secukinumab (Cosentyx) as a treatment for moderate to severe plaque psoriasis in pediatric patients at least 6 years old who are candidates for systemic therapy or phototherapy. https://t.co/vKkhXpZ6Qj
-
-
Mashup Score: 0
All patients with severe disease had abnormal ECG readings.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
“These findings may suggest that severe #SCA is associated with #cardiovascular abnormalities like left atrial abnormality, intraventricular conduction abnormalities, increased risk of arrhythmias, and sudden death." https://t.co/Coj5Xd3Q0L
-
-
Mashup Score: 1Intersections Between Climate Change and Dermatology - 3 year(s) ago
Misha Rosenbach, MD, discusses how rising temperatures and climate change, issues of public health concern, are relevant to the field of dermatology.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
“We see with #COVID that we’re all citizens of the same planet, and this is the only planet.” @BradMph and @MishaRosenbach discuss why dermatologists should care about #climatechange. #DermDiscussions https://t.co/PStFfxXdY6
-
-
Mashup Score: 0Earlier Wake Up Time Reduces Risk of Depression - 3 year(s) ago
New research sheds light on the relationship between sleep timing and the risk of developing major depressive disorder (MDD).
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
A new study shows waking up an hour earlier could substantially reduce the risk of depression. https://t.co/4FfVXMrdW5
-
-
Mashup Score: 0
The oral combination therapy can also be used as acute treatment for manic or mixed episodes.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
"With the efficacy of #olanzapine and evidence of less weight gain in patients with #schizophrenia, LYBALVI brings a welcome new addition to our medication arsenal." https://t.co/PcejObgwg0
-
-
Mashup Score: 0David M. Poppers, MD: Early Detection for Esophageal Cancer - 3 year(s) ago
Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
Esophageal cancer rates are rising, leading to a need for early detection screening tools. Dr. David Poppers explained how EsoCheck could transform diagnostics in this area. https://t.co/zA0CyXNnKP
-
-
Mashup Score: 0FDA Approves Ozanimod for Adults with Ulcerative Colitis - 3 year(s) ago
The treatment is also being studied for safety and efficacy in patients with Crohn’s disease.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: The #FDA last week approved ozanimod (Zeposia) 0.92 mg, an oral agent that selectively targets sphingosine-1-phosphate receptor subtypes 1 and 5, for adult patients with moderately to severely active ulcerative colitis. https://t.co/dtMiVVkiWM
-
-
Mashup Score: 1Intersections Between Climate Change and Dermatology - 3 year(s) ago
Misha Rosenbach, MD, discusses how rising temperatures and climate change, issues of public health concern, are relevant to the field of dermatology.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
Listen to the May episode of #DermDiscussions with @BradMph! .@MishaRosenbach discusses the relevance of #climatechange to #dermatology. https://t.co/PStFfxFD6y
-
-
Mashup Score: 0
The oral combination therapy can also be used as acute treatment for manic or mixed episodes.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
BREAKING: The #FDA has approved olanzapine and samidorphan combination therapy (LYBALVI) for the treatment of #schizophrenia and #bipolar I disorder. https://t.co/PcejOaYVos
-
"In #sicklecell disease, the #pain crises are so predominant, in your face, and this patient’s quality of life is so poor that they’re just used to it." - Patrick McGann, MD, MS (@PTMcGann), of @CincyChildrens https://t.co/q2xuhKkIyM https://t.co/A1LZRbIRgj